Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $5.5 million.

  • Apellis Pharmaceuticals' Other Non-Current Assets rose 27868.97% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 27868.97%. This contributed to the annual value of $1.3 million for FY2024, which is 305.58% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Other Non-Current Assets of $5.5 million as of Q3 2025, which was up 27868.97% from $898000.0 recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Other Non-Current Assets high stood at $5.5 million for Q3 2025, and its period low was $898000.0 during Q2 2025.
  • In the last 5 years, Apellis Pharmaceuticals' Other Non-Current Assets had a median value of $1.3 million in 2024 and averaged $1.5 million.
  • Data for Apellis Pharmaceuticals' Other Non-Current Assets shows a peak YoY increase of 27868.97% (in 2025) and a maximum YoY decrease of 3293.5% (in 2025) over the last 5 years.
  • Over the past 5 years, Apellis Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $1.6 million in 2021, then fell by 18.55% to $1.3 million in 2022, then rose by 2.83% to $1.3 million in 2023, then rose by 3.06% to $1.3 million in 2024, then soared by 307.04% to $5.5 million in 2025.
  • Its Other Non-Current Assets stands at $5.5 million for Q3 2025, versus $898000.0 for Q2 2025 and $1.4 million for Q1 2025.